EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY 4.0

Alteration of BDNF, SPARC, FGF-21, and GDF-15 circulating levels after 1 year of anti-obesity treatments and their association with 1-year weight loss

Kusuma Chaiyasoot, Nanta Khumkhana, Wanjan Deekum, Chartchai Chaichana, Voraboot Taweerutchana, Nicha Srisuworanan, Pornpoj Pramyothin

Endocrine · 12.07.2023 · 82 (1) · 57-68

DOI: 10.1007/s12020-023-03435-2 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Endocrine, online erschienen am 12.07.2023. Verfasst von Kusuma Chaiyasoot und 6 weiteren Autor:innen. Beteiligte Einrichtung: Division of Nutrition, Department of Medicine, Mahidol University, Bangkok, Thailand. Hauptthemen laut MEDLINE: Brain-Derived Neurotrophic Factor, Insulin Resistance. Die Arbeit wurde bisher 12-mal zitiert (Crossref) und nennt 43 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Health Science Research Institute (HSRI).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

Emerging evidence revealed that brain-derived neurotrophic factor (BDNF), secreted protein acidic and rich in cysteine (SPARC), fibroblast growth factor 21(FGF-21) and growth differentiation factor 15 (GDF-15) are involved in energy metabolism and body weight regulation. Our study aimed at examining their association with BMI, their alterations after anti-obesity treatments, and their association with 1-year weight loss.

Methods

A prospective observational study of 171 participants with overweight and obesity and 46 lean controls was established. All participants received lifestyle educational intervention (LEI) with or without anti-obesity treatments (LEI + bariatric/metabolic surgery, n = 41; LEI + topiramate, n = 46; LEI + liraglutide, n = 31; LEI + orlistat, n = 12; and LEI alone, n = 41). Anthropometric and metabolic parameters, insulin sensitivity, C-reactive protein (CRP), fasting plasma levels of BDNF, SPARC, GDF-15, and FGF-21 were measured at baseline and 1 year.

Results

Multiple linear regression showed that fasting levels of SPARC, FGF-21, and GDF-15 were significantly associated with baseline BMI after adjustment for age and sex. At 1 year, the average weight loss was 4.8% in the entire cohort with a significant improvement in glycemia, insulin sensitivity, and CRP. Multiple linear regression adjusted for age, sex, baseline BMI, type of treatment, and presence of T2DM revealed that the decrease in log 10 FGF-21 and log 10 GDF-15 at 1 year from baseline was significantly associated with a greater percentage of weight loss at 1 year.

Conclusions

This study highlights the association of SPARC, FGF-21, and GDF-15 levels with BMI. Decreased circulating levels of GDF-15 and FGF-21 were associated with greater weight loss at 1 year, regardless of the types of anti-obesity modalities.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Brain-Derived Neurotrophic FactorInsulin ResistanceHumansGrowth Differentiation Factor 15OsteonectinObesityWeight LossFibroblast Growth Factors

Substanzen

Brain-Derived Neurotrophic FactorGrowth Differentiation Factor 15Osteonectinfibroblast growth factor 21Fibroblast Growth FactorsSPARC protein, human

Autor:innen und Institutionen

  • Division of Nutrition, Department of Medicine, Mahidol University, Bangkok, Thailand.
  • Siriraj Center of Research Excellence for Diabetes and Obesity, Mahidol University, Bangkok, Thailand.
  • Division of Minimal Invasive Surgery, Department of Surgery, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
  • Division of Nutrition, Department of Medicine, Mahidol University, Bangkok, Thailand. pornpoj.pra@mahidol.edu.

Förderung

  • Health Science Research Institute (HSRI)

Zitieren

APA

Chaiyasoot, K., Khumkhana, N., Deekum, W., Chaichana, C., Taweerutchana, V., Srisuworanan, N., & Pramyothin, P. (2023). Alteration of BDNF, SPARC, FGF-21, and GDF-15 circulating levels after 1 year of anti-obesity treatments and their association with 1-year weight loss. Endocrine, 82(1), 57-68. https://doi.org/10.1007/s12020-023-03435-2

Vancouver

Chaiyasoot K, Khumkhana N, Deekum W, Chaichana C, Taweerutchana V, Srisuworanan N, et al. Alteration of BDNF, SPARC, FGF-21, and GDF-15 circulating levels after 1 year of anti-obesity treatments and their association with 1-year weight loss. Endocrine. 2023;82(1):57-68. doi:10.1007/s12020-023-03435-2

BibTeX
@article{Chaiyasoot2023,
  author = {Chaiyasoot, Kusuma and Khumkhana, Nanta and Deekum, Wanjan and Chaichana, Chartchai and Taweerutchana, Voraboot and Srisuworanan, Nicha and Pramyothin, Pornpoj},
  title = {Alteration of BDNF, SPARC, FGF-21, and GDF-15 circulating levels after 1 year of anti-obesity treatments and their association with 1-year weight loss},
  journal = {Endocrine},
  year = {2023},
  volume = {82},
  number = {1},
  pages = {57--68},
  doi = {10.1007/s12020-023-03435-2}
}
Kostenlos starten →